Number of people with dementia in EU set to double by 2050

18 February 2020

At a European Parliament lunch debate hosted by Christophe Hansen MEP (Luxembourg) today, the non-profit non-governmental organization (NGO) Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates for dementia in Europe.

The key findings of Alzheimer Europe's report include:

Across men and women and across most age groups, there has been a reduction in the prevalence of dementia over the past 10 years when compared to 2008 estimates.
The number of people living with dementia in the European Union (EU27) is estimated to 7,853,705 and in European countries represented by AE members, 9,780,678. Compared to its earlier estimates, this constitutes a significant reduction from 8,785,645 for the EU27 and from 10,935,444 for the broader European region.
Women continue to be disproportionately affected by dementia with 6,650,228 women and 3,130,449 men living with dementia in Europe.
The numbers of people with dementia in Europe will almost double by 2050 increasing to 14,298,671 in the European Union and 18,846,286 in the wider European region.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK